Background
==========

According to World Health Organization (WHO) estimations \[[@B1]\], access to combination antiretroviral treatment (cART) has improved dramatically in low- and middle-income countries with limited resources. At the end of 2009, almost 5.3 million people were receiving antiretroviral therapy in low- and middle-income countries, an increase of more than 1.2 million people from December 2008. In addition, with the newly updated treatment guidelines, the number of people estimated to be in need of cART increased from 10 million to close to 15 million at the end of 2009.

Zidovudine (AZT) was recommended by WHO \[[@B2]\] as a first-line regimen in combination with another nucleoside reverse transcriptase inhibitor (NRTI) and a non-nucleoside reverse transcriptase inhibitor (NNRTI). AZT was also used as an alternate for patients switching from stavudine (d4T) to AZT due to toxicity, or as part of the treatment programme\'s systematic effort to avoid long-term toxicity issues associated with d4T toxicity \[[@B3],[@B4]\]. The 2010 WHO guidelines recommend that countries using d4T in their first-line regimens phase d4T out and replace it with either AZT or tenofovir in order to prevent long-term toxicity \[[@B2]\].

There have been reports of the short-term tolerability related to the use of AZT, in particular the development or worsening of anaemia. Anaemia was associated with previous clinical AIDS disease or other infection, CD4 count, HIV viral load, female sex, age, and low body mass index \[[@B5]-[@B7]\]. Given the recent change in WHO guidelines, there was some concern that rates of anaemia may increase with the transition from d4T-containing regimens to AZT-containing regimens.

The objective was to examine the short-term risk and predictors of anaemia following initiation of cART in HIV-infected patients from the Western Africa (WA), Eastern Africa (EA), Southern Africa (SA), Central Africa (CA), Asian (TA) and Caribbean and Central and South America (CSA) regions of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) collaboration.

Methods
=======

Study population: the IeDEA collaboration
-----------------------------------------

The IeDEA initiative of the U.S. National Institutes of Health has established international regional centres for the collection and harmonization of data and the establishment of an international research consortium to address unique and evolving research questions in HIV/AIDS currently unanswerable by single cohorts \[[@B8]\]. Clinically derived HIV treatment data is being collected by researchers throughout the world. This initiative provides a means to establish and implement methodologies to effectively pool the collected data from regions around the globe, thus providing a cost-effective means of generating large data sets to address high-priority research questions related to HIV/AIDS care.

By developing a proactive mechanism for the collection of key variables, this initiative will enhance the quality cost effectiveness and speed of HIV/AIDS research. The sources that support the IeDEA research agenda include independently funded investigators and clinical networks, domestic and international cohorts, individual clinicians caring for large numbers of HIV-infected persons, and national or local databases. Currently, there are seven IeDEA regions: Canada and United States; Caribbean and Central and South America; Asia and Pacific; Western Africa; Central Africa; Eastern Africa; and Southern Africa. Data from more than 300,000 HIV-infected persons from 38 different countries are currently included under this initiative. Details of the IeDEA initiative can be found at <http://www.iedea.org/>. The IeDEA regions that participated in this analysis were the Western Africa \[[@B9]\], Southern Africa \[[@B10]\] and Eastern Africa \[[@B11]\], Central Africa \[[@B12]\], Asia-Pacific regions \[[@B13]\] and Caribbean and Central and South America \[[@B14]\].

Adult patients (age \> 18 years) were included if they initiated cART regimens that contained three or more drugs and had haemoglobin levels above 10 g/dL within 90 days prior to cART initiation, and at least one follow-up haemoglobin test.

Procedures and statistical analysis
-----------------------------------

### Study procedures

The concept for this analysis was reviewed and approved by the IeDEA Executive Committee and all the participating regional steering committees. The data elements in this analysis included baseline and demographic data, HIV disease staging according to

Centers for Disease Control and Prevention (CDC) and/or WHO classification, CD4 and HIV viral load testing, antiretroviral treatment, haemoglobin testing, and weight and height measurements. The regional data centres reviewed and extracted the requested data from their regional databases or requested the identified variables from designated programmes within their regions.

The data were then centrally aggregated and analysed at The Kirby Institute in Sydney, Australia, the regional data centre of the Asia-Pacific IeDEA region. Data consistency checks were conducted when the data were received. This included queries on apparent data-entry errors, out-of-range testing results, antiretroviral treatment combinations that fell outside of the standard of care (for example, AZT concurrent with d4T), and possible data-entry error, such as dates of starting and stopping cART.

The IeDEA Pharmacovigilance and Data Harmonisation Working Groups, comprised of members from each IeDEA region, facilitated the early stage of concept development, as well as later data collection and preparation of the analytical datasets.

### Statistical analysis

We used the NIH Division of AIDS definitions for Grading the Severity of Adult and Paediatric Adverse Events \[[@B15]\]. Anaemia was defined as a haemoglobin level of \< 10 g/dL, and severe anaemia as a haemoglobin level of \< 7.5 g/dL.

Mean change of haemoglobin level from cART initiation to 36 months was graphically represented in patients with baseline and follow-up haemoglobin tests. The proportions of patients with anaemia at month 12 after initiation of antiretroviral treatment were tabulated by baseline haemoglobin level and stratified by initial AZT or d4T use. Time to anaemia and severe anaemia within 12 months of cART initiation was assessed by survival analysis. Patients tested but not found to be anaemic were censored at month 12. Factors associated with anaemia were examined using Cox proportional hazards models and stratified by IeDEA region.

Due to the fact that the proportions of patient initiating AZT-containing cART were different across the IeDEA regions, we further investigated the interaction term between AZT use and IeDEA region in predicting anaemia at 12 months. In these analyses, the risk factors for anaemia identified in the main Cox model, and their directions and magnitude, remained largely the same, indicating the robustness of our analyses (data not shown). The analysis was performed using SAS (version 9.1, SAS Institute Inc., Cary, North Carolina, USA) and STATA (version 10.1, StataCorp, College Station, Texas USA).

Results
=======

The baseline characteristics are shown in Table [1](#T1){ref-type="table"}. The number of cohorts contributing patients varied between IeDEA regions: 12 in WA, one in EA, seven in SA, 10 in CA, one in TA, and three in CSA. A total of 19,947 patients initiated cART containing three or more drugs and each had a baseline haemoglobin test and at least one follow-up haemoglobin test (7358 in WA, 7289 in EA, 2853 in SA, 471 in CA, 1550 in TA and 426 in CSA).

###### 

Patient characteristics at cART initiation

                                                                            West Africa       Eastern Africa    Southern Africa    Central Africa     Asia-Pacific       Central & South America   Total
  ------------------------------------------------------------------------- ----------------- ----------------- ------------------ ------------------ ------------------ ------------------------- -----------------
  No. cohorts in database                                                   12                1                 7                  10                 1                  3                         34
  No. patients in database                                                  14340             8992              3459               18047              4074               1644                      50556
  No. initiating cART with 3 or more antiretrovirals                        12502             8971              3357               4715               3501               1644                      34690
  No. with haemoglobin at initiation                                        10823             7326              3265               2215               1754               460                       25843
  No. with follow up haemoglobin test                                       7358              7289              2853               471                1550               426                       19947
  (among patients with haemoglobin at initiation)                                                                                                                                                  
  Year cART was initiated                                                                                                                                                                          
  Median (IQR)                                                              05 (04,06)        05 (05,06)        05 (04,06)         09 (08,09)         04 (02,05)         04 (02,05)                05 (04, 06)
  Gender                                                                                                                                                                                           
  Male                                                                      2665 (36%)        2876 (39%)        672 (24%)          142 (30%)          1097 (71%)         270 (63%)                 7722 (39%)
  Female                                                                    4693 (64%)        4413 (61%)        2181 (76%)         329 (70%)          453 (29%)          156 (37%)                 12225 (61%)
  Age (years, at initiation)                                                                                                                                                                       
  Median (IQR)                                                              37 (31,43)        38 (33,45)        34 (29,40)         39 (33,45)         35 (30,42)         37 (31,44)                37 (31,44)
  \< = 30                                                                   1661 (23%)        1176 (16%)        891 (31%)          72 (18%)           442 (27%)          99 (23%)                  4321 (22%)
  31\~40                                                                    3116 (42%)        3054 (43%)        1257 (44%)         166 (36%)          669 (43%)          182 (43%)                 8444 (43%)
  41+                                                                       2581 (35%)        2985 (41%)        705 (25%)          167 (36%)          459 (30%)          145 (34%)                 7042 (35%)
  Missing                                                                   0                 74                0                  66                 0                  0                         140
  Reported exposure                                                                                                                                                                                
  Heterosexual contact                                                      2127 (100%)       1540 (100%)       2825 (100%)        236 (99%)          1057 (76%)         289 (99%)                 8074 (96%)
  Homosexual contact                                                        0 (0%)            0 (0%)            0 (0%)             2 (1%)             299 (21%)          0 (0%)                    301 (4%)
  Injecting drug use                                                        0 (0%)            0 (0%)            0 (0%)             0 (0%)             40 (3%)            3 (1%)                    43 (\< 1%)
  Other/unknown                                                             5231              5749              28                 233                154                134                       11529
  Haemoglobin level at initiation (g/dL, within 90 days before intiation)                                                                                                                          
  Median (IQR)                                                              10.1 (9.0,11.5)   11.2 (9.6,12.8)   11.2 (10.0,13.0)   10.1 (9.4, 11.8)   12.2 (10.8,13.8)   12.0 (11.0,14.0)          10.9 (9.4,12.4)
  \> = 10 g/dL                                                              4057 (55%)        5142 (71%)        2257 (79%)         304 (64%)          1317 (85%)         368 (86%)                 13445 (68%)
  7.5\~ \< 10 g/dL                                                          2738 (37%)        1773 (24%)        517 (18%)          156 (33%)          206 (13%)          51 (12%)                  5411 (27%)
  6.5\~ \< 7.5 g/dL                                                         365 (5%)          224 (3%)          46 (2%)            8 (2%)             18 (1%)            5 (1%)                    666 (3%)
  \< 6.5 g/dL                                                               198 (3%)          150 (2%)          33 (1%)            3 (1%)             9 (1%)             2 (\< 1%)                 395 (2%)
  Haemoglobin test after initiation (up to year one)                                                                                                                                               
  Median number of tests (IQR)                                              1 (1,2)           1 (1,2)           2 (1,3)            1 (1,2)            3 (1,4)            3 (1,5)                   1 (1,2)
  Median days from initiation                                                                                                                                                                      
  to the first test (IQR)                                                   217 (180,337)     212 (163,342)     294 (186,339)      104.5 (14, 210)    282 (194,336)      274 (170,331)             239 (175, 338)
  CD4 count at initiation (cells/mm^3^, within 90 days before initiation)                                                                                                                          
  Median (IQR)                                                              136 (56,220)      101 (44,166)      87 (32,155)        148.5 (62, 228)    112 (35,204)       120 (50,212)              112 (45,187)
  \< = 50                                                                   1662 (24%)        1907 (28%)        904 (34%)          63 (22%)           451 (33%)          92 (27%)                  5079 (27%)
  51\~100                                                                   1090 (15%)        1506 (22%)        565 (22%)          38 (13%)           214 (15%)          60 (18%)                  3473 (19%)
  101+200                                                                   2223 (31%)        2512 (36%)        833 (32%)          94 (32%)           263 (26%)          96 (28%)                  6121 (33%)
  201+                                                                      2137 (30%)        946 (14%)         321 (12%)          95 (33%)           364 (26%)          93 (27%)                  3956 (21%)
  Not available                                                             246               418               230                181                158                85                        1318
  HIV RNA at initiation (copies/mL, within 90 days before initiation)                                                                                                                              
  Median                                                                    165600            5565              52702              4900               119500             91000                     72274.5
  (IQR)                                                                     31462, 550025     400, 39600        14041, 184563      \< 400, 46155      30000, 413273      9000, 160000              17400, 270000
  \< 400                                                                    7 (5%)            5 (50%)           109 (8%)           3 (27%)            31 (5%)            17 (12%)                  175 (7%)
  400\~10,000                                                               10 (8%)           0 (0%)            157 (11%)          3 (27%)            55 (8%)            18 (13%)                  240 (10%)
  10,001\~100,000                                                           34 (26%)          4 (40%)           633 (46%)          3 (27%)            235 (35%)          57 (42%)                  966 (41%)
  100,001+                                                                  81 (61%)          1 (10%)           491 (35%)          2 (19%)            357 (52%)          45 (33%)                  977 (42%)
  Not available                                                             7226              7279              1463               460                872                289                       19947
  Disease stage: CDC 3 or WHO 4                                                                                                                                                                    
  No                                                                        3185 (74%)        6048 (90%)        2349 (83%)         160 (34%)          827 (53%)          138 (37%)                 12707 (78%)
  Yes                                                                       1118 (26%)        639 (10%)         491 (17%)          311 (66%)          723 (47%)          236 (63%)                 3518 (22%)
  Not known                                                                 3055              602               13                 0                  0                  52                        3722
  Tuberculosis co-infection                                                                                                                                                                        
  No                                                                        6369 (87%)        5345 (73%)        2532 (89%)         17 (4%)            1240 (80%)         396 (92%)                 15899 (80%)
  Yes                                                                       989 (13%)         1944 (27%)        321 (11%)          454 (96%)          310 (20%)          30 (7%)                   4048 (20%)
  Use of TMP-SMX                                                                                                                                                                                   
  No                                                                        2949 (40%)        2972 (41%)        \-\--              330 (70%)          741 (48%)          \-\--                     6992 (42%)
  Yes                                                                       4409 (60%)        4317 (59%)        \-\--              141 (30%)          809 (52%)          \-\--                     9676 (58%)
  Not known                                                                 0                 0                 2853                                                     426                       3279
  Initial cART combination containing AZT                                                                                                                                                          
  No                                                                        4787 (65%)        7000 (96%)        2099 (74%)         190 (40%)          938 (60%)          89 (21%)                  15103 (76%)
  Yes                                                                       2571 (35%)        289 (4%)          754 (26%)          281 (60%)          612 (40%)          337 (79%)                 4844 (24%)
  Initial cART combination containing d4T                                                                                                                                                          
  No                                                                        2813 (38%)        291 (4%)          760 (27%)          297 (63%)          725 (47%)          341 (80%)                 5227 (26%)
  Yes                                                                       4545 (62%)        6998 (96%)        2093 (73%)         174 (37%)          825 (53%)          85 (20%)                  14720 (74%)
  Initial treatment combination (top 4 most frequent)                                                                                                                                              
  d4T/3TC/NVP                                                               2414 (33%)        5978 (82%)        415 (15%)          149 (32%)          560 (36%)          46 (11%)                  9562 (48%)
  d4T/3TC/EFV                                                               1507 (20%)        919 (12%)         1668 (58%)         22 (5%)            111 (7%)           24 (6%)                   4251 (21%)
  AZT/3TC/EFV                                                               1398 (19%)        54 (\< 1%)        441 (15%)          52 (11%)           249 (16%)          261 (61%)                 2455 (12%)
  AZT/3TC/NVP                                                               392 (5%)          201 (3%)          280 (10%)          224 (48%)          162 (11%)          20 (5%)                   1279 (6%)

Most patients included in this analysis started cART in 2004 and 2005, except those from CA, who started more recently (median 2009). There were more female patients in WA, EA, SA and CA compared with TA and CSA, which had a majority of male patients. In each region, more than 40% of patients were aged between 30 and 39 years. The information on exposure was missing in more than 70% of patients from WA and EA; however, heterosexual contact is the most reported category in all regions (Table [1](#T1){ref-type="table"}).

At initiation, anaemia and severe anaemia were found in 37% and 8% of patients from WA, 24% and 5% from EA, 18% and 3% from SA, 33% and 3% from CA, 13% and 2% from TA, and 12% and 2% from CSA, respectively (Table [1](#T1){ref-type="table"}). Within 12 months of cART initiation, patients from WA, EA and CA had a median of one haemoglobin test, patients from SA had two tests, and patients from TA and CSA had three tests. The median number of days from initiation to the first haemoglobin test was 217, 212, 294, 104.5, 282 and 274 days in patients from WA, EA, SA, CA, TA and CSA, respectively.

At cART initiation, the patients in each region had median CD4 counts between 101 and 148 cells/mm^3^and more than half of the patients did not have a baseline HIV RNA test (Table [1](#T1){ref-type="table"}). The proportion of patients with either CDC stage three or WHO stage four varies in different regions, from 9% in EA to 66% in CA. Tuberculosis co-infection was reported in all regions, ranging from 7% in CSA to 96% in CA. Use of co-trimoxazole (TMP-SMX) was reported in 60% of patients in WA, 59% in EA and 52% in TA.

The most frequent cART regimen at treatment initiation was a three-drug combination of two NRTIs (the majority either with d4T+3TC or AZT+3TC), plus one NNRTI (either with NVP or EFV). An AZT-containing regimen was initiated in 35% of patients in WA, 4% in EA, 26% in SA, 60% in CA, 40% in TA, and 79% in CSA. In each of the IeDEA regions, patients with more severe anaemia were generally more likely to initiate with a non-AZT-containing regimen (Figure [1](#F1){ref-type="fig"}).

![**Proportions of AZT-containing cART by region and baseline haemoglobin level**.](1758-2652-15-5-1){#F1}

The mean change in haemoglobin from cART initiation is shown in Figure [2](#F2){ref-type="fig"}. In patients initiating AZT-containing cART, there was an initial mean haemoglobin decrease of approximately 0.5 g/dL in the first three months; in patients starting with non-AZT-containing cART, there was an immediate haemoglobin increase after initiation. From three months after treatment initiation, there was a mean difference of approximately 1 g/dL between patients initiating AZT-containing cART and those initiating with non-AZT-containing cART that persisted for up to 36 months.

![**Mean change of haemoglobin since initiation of cART**.](1758-2652-15-5-2){#F2}

A total of 13,445 (68%) patients initiated cART with normal haemoglobin, 4057 (55%) in WA, 5142 (71%) in EA, 2257 (79%) in SA, 304 (64%) in CA, 1317 (85%) in TA, and 368 (86%) in CSA. Within 12 months of cART initiation, the risks of severe anaemia were 3.9 per 100 person-years (95% confidence interval, CI, 3.6-4.2) and varied from 2.3 (2.0\~2.7) in EA to 10.2 (7.1\~14.1) in CA; the overall risks of any anaemia (including severe anaemia) were 11.5 per 100 person-years (11.0, 12.1) and varied from 6.6 (5.9\~7.4) in EA to 22.9 (31.6\~45.3) in CA (Table [2](#T2){ref-type="table"}).

###### 

Risk of anaemia (\< 10 g/dL) within 12 months after ART initiation among patients with normal haemoglobin (\> = 10 g/dL)

                                                                            **No**.   Follow up   **No**.   Rate   Univariate analysis   Multivariate analysis                           
  ------------------------------------------------------------------------- --------- ----------- --------- ------ --------------------- ----------------------- ----------------------- --------------
  Total                                                                     13445     11893       1373      11.5                                                                         
  IeDEA region (analyses were stratified by IeDEA region)                                                                                                                                
  Western Africa                                                            4057      3361        612       18.2                                                                         
  Eastern Africa                                                            5142      4825        320       6.6                                                                          
  Southern Africa                                                           2257      2035        197       9.7                                                                          
  Central Africa                                                            304       214         49        22.9                                                                         
  Asia-Pacific                                                              1317      1156        136       11.8                                                                         
  Central & South America                                                   368       302         59        19.5                                                                         
  Gender                                                                                                                                                                                 
  Male                                                                      6000      5344        471       8.8    reference                                     reference               
  Female                                                                    7445      6549        902       13.8   1.65                  \< 0.001                **1.33 (1.18, 1.50)**   **\< 0.001**
  Age (years, at initiation)                                                                                                                                                             
  \< = 30                                                                   2668      2342        328       14.0   reference                                     reference               
  31\~40                                                                    5697      5053        577       11.4   0.84                  0.014                   0.96 (0.83, 1.10)       0.532
  41+                                                                       4964      4420        455       10.3   0.78                  0.001                   0.96 (0.83, 1.11)       0.583
  Missing                                                                   96        78          13        16.7   1.10                  0.739                   1.16 (0.64, 2.10)       0.622
  Baseline haemoglobin (g/dL)                                                                                                                                                            
  13+                                                                       3826      3552        136       3.8    reference                                     reference               
  12 to \< 13                                                               2726      2485        160       6.4    1.67                  \< 0.001                **1.51 (1.19, 1.90)**   **0.001**
  11 to \< 12                                                               3389      2961        398       13.4   3.46                  \< 0.001                **2.96 (2.42, 3.62)**   **\< 0.001**
  10 to \< 11                                                               3504      2895        679       23.4   5.95                  \< 0.001                **4.94 (4.06, 6.01)**   **\< 0.001**
  CD4 count at initiation (cells/mm^3^, within 90 days before initiation)                                                                                                                
  101+                                                                      7138      6408        598       9.3    reference                                     reference               
  51\~100                                                                   2224      1986        218       11.0   1.18                  0.037                   **1.24 (1.06, 1.45)**   **0.007**
  \< = 50                                                                   3187      2753        417       15.1   1.62                  \< 0.001                **1.65 (1.45, 1.87)**   **\< 0.001**
  Not available                                                             896       746         140       18.8   1.99                  \< 0.001                **1.71 (1.41, 2.08)**   **\< 0.001**
  Disease stage: CDC 3 or WHO 4                                                                                                                                                          
  No                                                                        8775      7930        761       9.5    reference                                     reference               
  Yes                                                                       2263      1882        350       17.9   1.54                  \< 0.001                **1.30 (1.13, 1.50)**   **\< 0.001**
  Not known                                                                 2407      2081        262       12.6   0.80                  0.005                   0.86 (0.73, 1.00)       0.057
  Tuberculosis co-infection                                                                                                                                                              
  No                                                                        10958     9721        1098      11.3   reference                                     reference               
  Yes                                                                       2487      2172        275       12.7   1.20                  0.013                   0.95 (0.81, 1.10)       0.496
  Initial ARV combination containing AZT                                                                                                                                                 
  No                                                                        9760      8988        716       8.0    reference                                     reference               
  Yes                                                                       3685      2905        657       22.6   12.43                 \< 0.001                **2.51 (2.22, 2.83)**   **\< 0.001**
  Initial ARV combination containing d4T                                                                                                                                                 
  No                                                                        3906      3093        677       21.9   reference                                     reference               
  Yes                                                                       9539      8800        696       7.9    0.47                  \< 0.001                0.82 (0.54, 1.25)       0.356
  Use of TMP-SMX                                                                                                                                                                         
  No/Not known                                                              7330      6481        706       10.9   reference                                     reference               
  Yes                                                                       6115      5412        667       12.3   1.14                  0.032                   1.01 (0.89, 1.14)       0.929

Factors associated with developing anaemia 12 months after cART initiation were (Table [2](#T2){ref-type="table"}): female gender (33% increase of risk compared with males); low baseline haemoglobin level (significant increase of risk with decreasing haemoglobin at baseline); low baseline CD4 count (significant increase of risk with decreasing CD4 count at baseline); advanced disease stage (30% increase of risk compared with lesser disease stage); initial AZT-containing cART (150% increase of risk compared with patients initiating non-AZT-containing cART). Tuberculosis co-infection and using of TMP-SMX were statistically significant in univariate analysis, but lost significance after adjustment.

Risks of anaemia by initial cART (AZT-containing or not) by IeDEA region are plotted in Figure [3](#F3){ref-type="fig"}. In patients from WA, EA, SA and TA, patients initiated with an AZT-containing cART had an increased risk of developing anaemia when compared with those initiating a non-AZT-containing regimen (p \< 0.001, respectively). The difference between the AZT and non-AZT groups in CA and CSA was not statistically significant after adjusting for the factors just outlined (CA, p = 0.088; CSA, p = 0.396).

![**Risk of anaemia (\< 10 g/dL) by initial cART and region**.](1758-2652-15-5-3){#F3}

Table [3](#T3){ref-type="table"} shows the proportions of patients with anaemia at month 12 after initiation of antiretroviral treatment by baseline haemoglobin level and stratified by initial AZT or d4T use. The table shows that for both AZT and d4T, the proportion of patients with anaemia is associated with baseline haemoglobin level. However, in patients starting with AZT, the proportion of anaemic patients remains high even in patients with baseline haemoglobin from 12 to \< 13 g/dL (13%). The proportion of anaemic patients is lower in patients stating d4T in each category of baseline haemoglobin, typically those above 11 g/dL.

###### 

Prevalence of anaemia (\< 10 g/dL) at month 12 following ARV initiation

               Initial ARV combination containing AZT   Initial ARV combination containing d4T                
  ------------ ---------------------------------------- ---------------------------------------- ------------ ------------
  13+          988 (93%)                                79 (7%)                                  2607 (98%)   56 (2%)
  12\~ \< 13   664 (87%)                                95 (13%)                                 1881 (97%)   60 (3%)
  11\~ \< 12   734 (79%)                                197 (21%)                                2218 (92%)   198 (8%)
  10\~ \< 11   642 (69%)                                286 (31%)                                2137 (85%)   382 (15%)
  \< 10        487 (42%)                                672 (58%)                                3438 (66%)   1743 (34%)

Discussion
==========

In this study that included six IeDEA regions and 34 HIV treatment cohorts, we found that the risk of developing anaemia within the first year on cART was associated with female sex, low baseline haemoglobin, more advanced immune-deficiency (clinically and immunologically) and receiving an initial cART containing AZT. In addition, we found that d4T-containing regimens were being used more commonly than AZT-containing regimens, especially in patients with severe anaemia at cART initiation.

An initial haemoglobin decrease of approximately 0.5 g/dL in the first three months was observed in patients initiating AZT-containing cART, compared with an immediate haemoglobin increase after initiation in patients starting with non-AZT-containing cART. These data are consistent with results from a meta-analysis of six randomized trials in treatment-naïve patients receiving either AZT or d4T as part of the regimen \[[@B16]\]. In this meta-analysis, haemoglobin levels decreased with AZT-containing treatment by a mean of 0.4 g/dL and 0.2 g/dL at weeks 24 and 48, respectively, but increased with d4T-containing treatment by 0.45 g/dL and 0.58 g/dL, respectively. The DART study also reported low haemoglobin measures at week 4, and grade 4 anaemia (\< 6.5 g/dL) occurring at week 12 following initiation of an AZT-containing regimen \[[@B17]\].

The use of AZT+3TC and d4T+3TC as the preferred NRTIs in a regimen has been advocated by WHO since 2000 and are the most common NRTI combinations used in initial HIV treatment regimens in resource-limited settings \[[@B18],[@B19]\]. Until recently, d4T was preferred over AZT due to its lower requirement for laboratory monitoring, lower cost, and availability in fixed-dose combinations tablets, despite its poorer toxicity profile, in association with lactic acidosis, lipodystrophy and peripheral neuropathy. To avoid or minimize the d4T-related long-term toxicity, in 2006, WHO recommended a move away from d4T-containing regimens \[[@B20]\], and in 2009, emphasized this in advice on antiretroviral treatment \[[@B21]\]. This recommendation was in agreement with other treatment guidelines, such as those published by the United States Department of Health and Human Services \[[@B22]\] and the British HIV Association \[[@B23]\]. In settings where d4T-containing regimens were used as the major initial drugs, WHO recommended moves towards AZT- or tenofovir (TDF)-based first-line regimens.

Among patients included in this paper, the median year of cART initiation was 2004-05 in the respective IeDEA regions. The major initial cART regimen contained d4T rather than AZT, which reflects to a large extent the true situation in low- and middle-income countries with limited resources. Moreover, in each of the IeDEA regions, patients with severe anaemia were generally initiated with a non-AZT-containing cART, which was most likely due to the well-established association between anaemia and AZT use \[[@B5],[@B16],[@B24]\].

The crude rate of acquiring anaemia among patients with normal haemoglobin at cART initiation did vary somewhat across the IeDEA regions. This might be due to sampling mechanisms, or biases due to different patterns of haemoglobin testing in each region. For example, at cART initiation and during the course of treatment, patients who had haemoglobin tests might have been selected for testing because they were considered at higher risk of developing anaemia by the local clinician. However, the risks of severe anaemia seemed relatively rare and consistent across the regions. Similar finding was found previously in patients from Uganda and Zimbabwe in the DART trial \[[@B17]\].

Female sex, low baseline haemoglobin, more advanced immune-deficiency (clinically and biologically) and initial cART-containing AZT were associated with the risk of acquiring anaemia within 12 months of starting cART. These risk factors were reported in previous studies \[[@B3],[@B5]-[@B7],[@B17]\]. However, the majority of the patients across the IeDEA regions did not have HIV viral load measurement prior to cART initiation, and weight and height data were not generally available across the regions. Consequently, we could not examine the effects of HIV viral load and body mass index on the risk of acquiring anaemia. The use of TMP-SMX was significant in univariate analysis, which might have to do with other infection and the need for prophylaxis since TMP-SMX rarely causes anaemia \[[@B25]\].

We acknowledge several limitations to our study. First, the selection of patients with at least a baseline and one follow-up measurement of haemoglobin might have introduced a bias of selection: patients with documented haemoglobin measurements are more likely to be at risk of anaemia than patients without assessment. In principal, rapid onset of severe, life-threatening anaemia that resulted in loss to follow up and death without a subsequent haemoglobin measurement is a potential scenario in severely resource-limited settings.

Moreover, as this is an observational study, measurements of haemoglobin might not be comparable in every participating country. In addition, important determinants of anaemia, such as body mass index, nutrition intake and malaria status, were not available in the current data assembled for analysis, which made the direct comparison of the risk of anaemia between IeDEA regions difficult, if not impossible, to interpret. Consequently we stratified the region in the Cox regression model to assess the risk factors.

Conclusions
===========

With the continued rapid scaling up of cART, there is a need to monitor treatment-related toxicity, especially in countries with limited resources and where alternative treatments are not readily available. We found that treating patients earlier, with less immune-deficiency, and with a non-AZT-containing regimen are the only modifiable risk factors associated with anaemia. In countries where TDF-based NRTI regimens are not widely available, a short-term treatment of non-AZT-containing regimens (mostly d4T-containing), followed by a switch to AZT, is worth investigating in terms of efficacy, short- and long-term tolerability, and disease outcomes \[[@B26]-[@B28]\]. This could be potentially beneficial for patients at risk of developing anaemia, e.g., female gender, patients with low CD4 counts and patients with advanced disease stage. In addition, routine haemoglobin monitoring is recommended in patients initiating with AZT-containing cART, typically at week 4, 8, 12, or at least every three months \[[@B2],[@B17]\].
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